I
Overview
Indegene helps biopharmaceuticals, emerging biotech, and medical devices companies bring products to market and grow their impact across the lifecycle. It uses a digital-first approach that blends healthcare domain expertise, purpose-built technology, and an agile operating model to offer a range of solutions. The goal is to deliver personalized, scalable, and omnichannel experiences for patients and physicians, making product launches and ongoing market engagement more effective and efficient so healthcare organizations can be future-ready.
Work here?Claim your company
Simplify's take
What believers are saying
- Active customers grew from 73 to 91 in FY26, broadening revenue durability.
- North America generated 71.6% of FY26 revenue, keeping access to the largest market.
- Management said FY27 pipeline is stronger, more balanced, and GenAI wins are gaining traction.
What critics are saying
- Indegene faces a U.S. TCPA class-action settlement hearing on January 12, 2027.
- North America supplied 71.6% of FY26 revenue, exposing earnings to U.S. buyer pauses.
- If Cortex monetization stalls, Accenture and IQVIA can commoditize Indegene's premium margins.
What makes Indegene unique
- Cortex, launched February 2025, verticalizes GenAI for life-sciences workflows and MLR reviews.
- FY26 revenue reached ₹35,105 million, validating its domain-led commercialization model.
- MJL Life Sciences acquisition and London expansion deepen UK healthcare communications capability.
Help us improve and share your feedback! Did you find this helpful?